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The use of viruses to treat tumors has received renewed interest with the availability of genetically defined attenuated
mutants. Herpes simplex virus (HSV) type 1 in particular has been shown to be effective for tumors of neuronal origin.
However, the model systems used for these studies rely on the use of explanted tumor cells in immunodeficient animals.
We have used a recently developed transgenic mouse model, wherein mice spontaneously develop retinoblastomas, to
determine if a mutant HSV has a therapeutic effect against an endogenously arising tumor in an immunocompetent host.
The injection of 1 1 106 PFU of the neuroattenuated HSV-1/HSV-2 recombinant RE6 into the vitreous of transgenic mice
resulted in a significant inhibition of tumor growth compared to injection of medium alone (P  0.0063). Immunohistochemical
analysis of viral antigen showed that viral replication was restricted to focal areas of the tumors and the retinal pigment
epithelium. Viral growth was not significantly different in the eyes of transgene-positive and transgene-negative mice,
suggesting that enhanced replication in tumor cells may not explain the effects. Tumor cells in the treated eyes were
significantly less differentiated than those in the untreated eyes (P  0.04), suggesting that the virus may replicate better
in certain cell types in the tumors. Although the injection of RE6 resulted in a difference in tumor size, the treatment did
not result in the elimination of tumors in any of the mice. Improvements in the efficacy of tumor control are needed if this
therapy is to be of use. q 1997 Academic Press
Traditionally, malignancy is treated with surgery, radia- oma explant model. Subsequent studies with other tumor
tion, chemotherapy, or immunotherapy. Although these cell lines (13), additional HSV mutants (14, 16– 21), or
treatments are successful with some cancers, other HSV mutants in combination with ganciclovir (15) have
types of cancer respond less well. Tumors of neuronal provided additional support for the use of HSV mutants
origin are among those resistant to traditional treatments. for tumor therapy.
For example, high-grade malignant gliomas are the most These previous studies used model systems in which
common brain tumors in adults (1), and despite aggres- tumor cell lines were implanted into rodents. In addition,
sive therapy with traditional methods, the 5-year survival some of them also used immunodeficient nude (12– 16)
rate is less than 5% (2– 5). or SCID mice (18). The immunodeficient models do not
One potential alternative therapy is the use of geneti- allow for the study of the effects of an active immune
cally modified herpes simplex virus (HSV). The advan- response to the attenuated HSV as a possible positive
tages of HSV include its neurotropism and the existence or negative cofactor in the treatment. Tumors arise spon-
of avirulent mutant viruses that grow to high titer in divid- taneously and usually in the presence of functional im-
ing cells, but show reduced replication in terminally dif- munity, which can modulate direct cell killing by the virus
ferentiated cells (6– 10). Pioneering studies by Skinner and may enhance the response by recognition of new
et al. (11) showed that an HSV thymidine kinase (TK) cell surface antigens.
mutant could reduce the rate of tumor development. HSV encodes a gene, g134.5, that is required for com-
More recent studies using a genetically engineered dele- plete neurovirulence and growth in a number of cell types
tion mutant, dlspTK (12), showed a dose-dependent im- including neurons (7, 8, 10, 22– 28). Successful treatment
provement in survival using a nude mouse– human gli- of neuronal tumors in animal models has been reported
with several g134.5 mutants. Using a glioma cell implant
model in nude mice, Markert (14) showed that treatment1 To whom correspondence and reprint requests should be ad-
with RE6 and another g134.5 mutant, R3616, significantlydressed at University of Wisconsin Medical School, 6630 Medical Sci-
ences Center, 1300 University Avenue, Madison, WI 53706-1532. prolonged survival and eliminated the tumors in 67% of
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the mice. Chambers et al. (18), using a SCID mouse between 16 and 18 weeks of age and eyes were taken
model of human glioma, showed that treatment pro- for analysis at 3– 5 weeks postinjection. Treatment at this
longed survival in a dose-dependent fashion. Finally, time was chosen based on the growth characteristics of
Randazzo et al. (17) showed that a g134.5 mutant, 1716, the tumor (data not shown). At 16 to 18 weeks of age,
could increase survival time in an intracranial murine tumors have involved the full thickness of the retina and
melanoma model system. These results suggest that are beginning to extend into the vitreous. The analysis
g134.5 mutants have potential for therapy of neuronal at 3 to 5 weeks was chosen to allow for viral clearance.
tumors. For both studies, the left and right eyes were removed,
A transgenic model for heritable retinoblastoma in fixed in 10% buffered formalin, embedded in paraffin, sec-
which bilateral retinoblastomas arise spontaneously in tioned, and stained with hematoxylin and eosin. In the
the mice was recently described (29, 30). In this model, pilot study, three random sections of each eye were ex-
a transgene containing the SV40 large T-antigen (Tag) amined by a masked observer and the section with the
driven by the murine b-leutinizing hormone promoter largest tumor was chosen. The tumor area was calcu-
(LHb-Tag mice) expresses Tag in the retina. The Tag lated using a 2.5X objective and reticle. In the second
binds the p105 Rb protein (29), resulting in functional study, single sections from each eye were cut through
inactivation of Rb and the development of ocular tumors the pupil optic nerve axis, each section was digitized,
that, in their histopathology and clinical course, closely the tumor was traced, and the tumor area in square milli-
resemble human retinoblastoma. The LHb-Tag mice thus meters was calculated. These methods have been pub-
represent a model in which to test the use of attenuated lished previously (31, 32). Each eye was counted as a
HSV mutants for the treatment of malignancy that more single tumor.
accurately represents the situation in patients. To confirm that these methods result in random sam-
The RE6 strain of HSV was first described in 1983 pling of the eyes, we serially sectioned the right eyes of
as an avirulent HSV-1:HSV-2 intertypic recombinant (10). four mice and measured the ratio of tumor area to total
Subsequently, it was shown to be avirulent (PFU/LD50  eye area in each section. The results showed that the
11 106) due to a defect in theg134.5 gene which resulted ratio was the same from the optic nerve– pupil axis to at
in severely reduced replication in neuronal tissues (10, least 1 mm on each side (data not shown). At the optic
22). In this paper, we show that the attenuated HSV mu- nerve– pupil axis the ratios were 0.49 { 0.05, indicating
tant, RE6, when injected intravitreally into LHb-Tag that the size of the tumor in relation to the size of the
transgenic mice, results in a statistically significant re- eye is remarkably constant. These results suggest that
duction in retinoblastoma tumor size. This is the first
we are taking random representative samples of the tu-report of the use of an HSV mutant to treat a spontane-
mors using the method described for the second study.ously arising tumor in an immunocompetent animal and
The data were analyzed in two strata correspondingsupports the possible use of this therapeutic modality
to the two studies (33). As the stratification did not influ-for some cancers.
ence the estimates of treatment effect or significance,Transgene-bearing mice were produced by mating
it was dropped in the final analysis for simplicity. TwoLHb-Tag transgene-positive males with CB6F1/J (C57BL/
additional comparisons were available only in the sec-6J BALB/cJ) females (The Jackson Laboratory, Bar Har-
ond group: the treated vs control eye contrast in thebor, ME) and identifying transgene-positive offspring by
experimental animals, and the injected vs control eyePCR analysis of tail DNA using the 5* primer 5*-GACTTT-
contrast among the medium-only group. However, theGGAGGCTTCTGGGATGCAACTGAG-3* (SV40 Tag bases
major contrast between the eyes treated with RE6 in the4947– 4918) and the 3* primer GGCATTCCACCACTG-
experimental group and the injected eyes in the medium-CTCCCATTCATCAGT-5* (SV40 Tag bases 4527 – 4556),
only group was available for all eyes. This yielded the Pwhich resulted in a 421-bp product. High-titer stocks of
value of 0.0063 for treatment effect.the RE6 virus (10) (gift of Dr. John Yu, Massachusetts
Due to the presence of outliers in the form of a fewGeneral Hospital, Boston, MA) were prepared in African
very large tumors, tumor areas were subjected to thegreen monkey kidney (Vero) cells as we described pre-
logarithmic transformation. The logarithmic scale in-viously (6).
duced approximate normality so that standard normal-The effect of treatment with the RE6 virus was tested
theory confidence intervals and t tests were appropriatelyinitially in a pilot study using the right eyes from 16 mice.
used. Thus, the means and confidence intervals wereEight of these were injected with 1 1 106 PFU of RE6 in
calculated on the log scale and exponentiated. Relative5 ml of medium, and 8 received medium only. Based on
risks and their confidence intervals were computed fromthe results from the preliminary study, a second group
differencing means on the log scale and then exponenti-of 36 mice was tested. In this second study, 17 eyes
ating. The analysis was conducted using S-plus statisti-received virus and 19 eyes were injected with medium
cal software (33). All significance levels were obtainedonly. The left eye in these mice was not injected and
served as an uninjected control. All mice were treated via t tests, either two-sample, when comparing eyes in
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FIG. 1. Effect of treatment on tumor size (A), and the ratio of treated to control eyes (B). These results represent the combined analysis of the
data from the two studies.
different animals, or one-sample, when comparing in- (Fig. 1B). The mean ratio in tumor size between the in-
jected and the uninjected eyes in the medium-only groupjected and uninjected eyes in the same animal.
As shown in Fig. 1A, the mean tumor area in the virus- was 0.88 (95% confidence interval 0.61 – 1.28) and the
difference was not significant (P  0.24). This result indi-treated eyes was 1.97 mm2 (95% confidence interval
1.48 –2.61 mm2) compared to 2.54 mm2 (1.67– 3.85 mm2) cates that the injection of medium did not affect tumor
size. The mean ratio in tumor size in the virus-treatedfor the uninjected eyes in the virus-treated group. The
mean tumor area was 3.67 mm2 (2.59 – 5.18 mm2) for the group was 0.74 (0.56– 0.98). This difference was signifi-
cant (P  0.019), indicating that the virus treatment re-eyes injected with medium only compared to 3.14 mm2
(2.23– 4.42 mm2) for the uninjected eyes in the medium sulted in smaller tumors. When we compared the eyes
injected with virus to the eyes injected with medium, thecontrol group.
To assess the effect of the treatment we compared mean ratio was 0.54 (0.35– 0.83) and the difference was
highly significant (P  0.0063). It should be noted, how-the means of the ratios of the treated and untreated
eyes in the virus and medium-injected groups as well ever, that the 95% confidence intervals overlap in all
groups. Representative low-magnification examples ofas between the virus-injected and medium-injected eyes
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sections through an untreated eye and a virus-treated Injection of virus into immunocompetent animals might
be expected to induce an inflammatory response whicheye are shown in Figs. 2A and 2B respectively.
Morphological analysis of the tumors in the two groups could contribute to the antitumor activity. We therefore
compared the degree of inflammation in the virus-in-was also carried out to determine if there were differ-
ences in the degree of involvement of the choroid, vitre- jected (treated) and untreated tumors at 3 weeks post-
treatment using procedures described previously (31).ous, iris – ciliary body angle, cornea, retinal pigment epi-
thelium, and optic nerve. The criteria for this analysis The presence of inflammation was higher in the treated
eyes (44%) compared to the control eyes (31%). However,have been described previously (31). A defining charac-
teristic of retinoblastomas is the presence of Homer the groups were not significantly different (P 0.43) (data
not shown). When we characterized the inflammationWright rosettes, which represent attempts by the tumor
cells to differentiate into photoreceptors (23, 24). These with respect to cell type, by histological criteria, we found
that neutrophils were the predominant infiltrating cellrosettes are characterized by a central luscent space
that represents the attempt by the cells to form outer type; however, the comparisons between treated and un-
treated eyes failed to reveal significant differences withsegments. The cell bodies surrounding the outer seg-
ments have a relatively constant shape and size with a regard to the type of inflammatory cell (P  0.05) within
the tumor (data not shown).high nuclear-to-cytoplasmic ratio. As shown in Table 1,
the only differences noted were that the tumors in the To assess the distribution of virus in the eyes of the
treated mice, the right eyes of 16- to 18-week-oldRE6-treated eyes were less differentiated (P  0.03) and
had fewer Homer Wright rosettes (P  0.03) than the transgene-bearing mice were injected intravitreally with
1 1 106 PFU of RE6. At 3 days PI, the eyes were removed,control tumors. Figures 2C and 2D show representative
intermediate-magnification views of a virus-injected (2C) fixed in 10% buffered formalin, embedded in paraffin, and
sectioned. Immunohistochemical detection of viral anti-tumor and an uninjected (2D) tumor. The virus-injected
tumor shows an extensive area lacking the typical Homer gen was carried out using a commercially available kit
(Vectastain ABC, Vector Laboratories, Burlingame, CA)Wright rosettes compared to the uninjected tumor, in
which the majority of the cells are organized into ro- and commercially available primary anti-HSV antibody
(BO114, Dako Corp., Carpinteria, CA). Representative ex-settes. Higher magnification views in Figs. 2E and 2F
show the organized structure of the rosettes in the unin- amples of the immunohistochemical staining are shown
in Fig. 4. In tumor tissue, HSV antigen was detected onlyjected tumors compared to the pleomorphic cells and
disorganization in the virus-injected tumors. There was in focal areas (Fig. 4B) and did not appear to spread
extensively, even though viral titers were highest at thisno difference in the amount of necrosis in the two groups
at 3 to 5 weeks posttreatment. time (Fig. 3). Viral antigen was also present in retinal
pigment epithelial cells in focal areas (Fig. 4D). We foundTo test the hypothesis that the antitumor effect was
due to the ability of the RE6 virus to grow better in tumor no evidence of immunohistochemical staining in any
other ocular tissues.cells compared to normal eye tissue, we injected the
right eyes of transgene-positive or transgene-negative One possible mechanism for the selective effects of
the attenuated HSV on tumors is that the mutant viruseslittermates (five mice per group) with 1 1 106 PFU of RE6
and at various times postinfection (PI) we assayed the grow better in rapidly dividing tumor cells than in normal
tissues. For attenuated viruses lacking either viral thymi-eyes for the amount of infectious virus using procedures
we described previously (34). The results are shown in dine kinase or ribonucleotide reductase, this hypothesis
is consistent with the proposed role of these enzymesFig. 3. On Day 1 PI, the RE6 titers were 2 1 104 and 1
1 103 for the LHb-Tag-negative and LHb-Tag-positive in viral replication. However, the in vivo growth of mutant
viruses in tumor and normal tissue was not compared inmice, respectively. On Day 2 PI, the titers were 10-fold
higher in the LHb-Tag-negative mice. On Day 5 PI, there most of the previous studies (12 – 21). In the one previous
study using a g134.5 mutant where viral growth waswas only a 2-fold difference and by Day 7, infectious
virus had essentially cleared in both groups of mice. tested in vivo, replication was more efficient and pro-
longed in tumor cells compared to normal brain (17). InStatistical analysis (t test) failed to reveal significant dif-
ferences (P  0.05) in viral growth in the two groups. contrast, we found that viral growth in the eyes of LHb-
FIG. 2. Tumor histopathology. (A) Representative example of an untreated (control) eye (original magnification, 123). (B) RE6-treated eye from
the same animal. C, cornea; L, lens; T, tumor; N, optic nerve; R, retina (original magnification, 123). (C) Intermediate-magnification view of tumor
from an untreated eye showing Homer Wright rosettes (original magnification, 1230), some of which are marked with asterisks. (D) Intermediate-
magnification view of the tumor from an RE6-treated eye (original magnification, 1230). Note that some cells attempt to form rosettes but these
are poorly organized. Note also the variable morphology of the cells. (E) High-magnification view of a tumor from an untreated eye showing Homer
Wright rosettes with the central luscent space and surrounding cell bodies (original magnification, 1460). Note the uniformity in cell size and shape.
(F) High-magnification view of a tumor from an eye treated with RE6 (original magnification, 1460). Note the lack of rosettes and the variability in
cell size and shape.
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TABLE 1
Characteristics of Retinoblastoma Tumorsa
Treated (right eye) Untreated (left eye)b
Observation Number % Number % P c
Number of eyes graded 17d 100 16e 94 1
Tumor present 17 100 16 100 1
Retinal involvement Retina totally involved 5 29 4 16 1
% of retina uninvolved 58.13 ({33.58) 62.38 ({30.82) 0.63
Full thickness involvement 10 59 10 63 0.67
Invasion of other ocular Invasion of vitreous 7 41 4 25 0.43
structures Invasion of ciliary body 4 24 4 16 0.71
Invasion of iris 2 12 3 19 0.33
Invasion of angle 2 12 4 25 0.33
Invasion of cornea 0 — 1 6 0.33
Invasion of choroid 7 41 5 32 0.75
Optic nerve invasion 2 12 2 13 1
Calcification 12 71 9 56 0.5
% undifferentiated 34.69 ({28.37) 14.38 ({20.32) 0.03
Necrosis present 9 53 8 16 1
Rosettes Flexner-Wintersteiner rosettes 0 — 3 19 —
Homer Wright rosettes 65.5 ({29.15) 85.63 ({20.32) 0.03
a All data from the second study, sections through pupil optic nerve axis.
b Uninjected paired eyes.
c Unpaired t test.
d For statistical analysis only the 16 paired eyes were included.
e The intraocular contents of one eye were lost and could not be graded.
Tag-positive mice was not significantly different than in tumors. When considered together, these results suggest
the eyes of nontransgenic littermates (Fig. 3). Viral repli- that the differences in tumor size between virus-injected
cation, as measured by staining for viral antigen, was and control mice are not related to viral replication.
restricted to focal areas of the tumors and to limited Additional mechanisms for the selective antitumor ef-
regions of retinal pigment epithelium. The magnitude of fects include the induction of an inflammatory response
the antitumor effects seems surprising given the re- that kills tumor cells through bystander effects, or the
stricted distribution of viral antigen. However, these re- induction of tumor-specific immunity as a consequence
sults are similar to those of Randazzo et al. (17) and of viral infection. The observed inflammation in areas
suggest that the virus does not spread extensively in the positive for viral antigens at Day 3 PI is consistent with
possible bystander effects, but the data are not conclu-
sive. The presence of similar degrees of inflammation in
treated and untreated eyes in the same animal at 3 to 5
weeks PI makes it difficult to draw conclusions about
the induction of tumor-specific immunity and further stud-
ies are needed to distinguish the effect of these different
mechanisms.
Several morphological criteria of the tumors were also
analyzed. In addition to the significant difference in tumor
size, we found that the tumors in the treated mice were
less differentiated, having fewer Homer Wright rosettes
than the untreated tumors. These results are tentative
due to their marginal P values and the large number of
parameters that were measured. One possible interpre-
tation of this finding is that the virus preferentially infects
or is more cytolytic in the more differentiated population
of retinoblastoma cells in the tumor. This hypothesisFIG. 3. Replication of RE6 virus in the eyes of transgene-positive
would be consistent with previous results showing that(Rb/) and transgene-negative (Rb0) mice. Each data point is the mean
titer from five eyes. cell type and cell state affect the growth of g134.5 mu-
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tants (28). Further studies are needed to determine if the model may require injections at later than 16 to 18 weeks
when tumors are larger and direct intratumoral injectionRE6 virus preferentially replicates in more differentiated
tumor cells and whether this is related to the g134.5 is technically less difficult.
In summary, we have shown that treatment of sponta-mutation in RE6.
Although we have shown that intravitreal injection of neously arising retinoblastoma tumors in a transgenic
mouse model with a neuroattenuated HSV mutant (RE6)RE6 results in a significant difference in retinoblastoma
size, the 95% confidence intervals overlapped and we results in a significant difference in tumor size. This find-
ing represents the first report of successful treatment ofdid not achieve complete regression of the tumor in any
of the treated mice. This is in contrast to other reports a tumor with a mutant HSV without the use of tumor
explants. This model more closely mimics the situationwith neuronal cell implants in which elimination of the
tumors was achieved at least in a portion of the treated in the treatment of human cancer. More importantly, the
model will allow us to test viral treatment of tumors inanimals (14, 17, 21). The reason or reasons for our less
robust results are not clear, but there are several possi- situations where tumor alloantigens from explants are
not a significant factor. The fact that these animals arebilities. Several of these factors could also account for
the variability in the results as reflected in the overlap- immunocompetent will also allow us to examine the com-
bined effects of the immune response and viral infectionping 95% confidence intervals. Our data suggest that viral
growth, if it occurred at all, was not different between on tumor development.
the transgene-bearing mice and transgene-negative
mice, and lack of viral replication could have reduced
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